HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Consensus Recommendation of “Hold” by Brokerages

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) have received an average rating of “Hold” from the five ratings firms that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $16.80.

Several equities research analysts have weighed in on HCM shares. Weiss Ratings lowered HUTCHMED from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, June 29th. Bank of America reduced their price target on shares of HUTCHMED from $21.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, March 10th. Morgan Stanley set a $13.60 price target on shares of HUTCHMED in a research report on Thursday, May 28th. Finally, Wall Street Zen cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a report on Saturday, March 7th.

Institutional Investors Weigh In On HUTCHMED

Large investors have recently made changes to their positions in the company. Blue Trust Inc. boosted its position in shares of HUTCHMED by 131.5% during the fourth quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock worth $103,000 after buying an additional 4,378 shares during the period. Ameriprise Financial Inc. boosted its stake in HUTCHMED by 4.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock valued at $234,000 after purchasing an additional 698 shares in the last quarter. Bank of America Corp DE boosted its stake in HUTCHMED by 17.3% during the second quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock valued at $310,000 after buying an additional 3,035 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in HUTCHMED by 34.2% during the third quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock valued at $342,000 after purchasing an additional 5,538 shares during the last quarter. Finally, Janney Montgomery Scott LLC bought a new stake in HUTCHMED during the first quarter worth approximately $365,000. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Stock Performance

NASDAQ:HCM opened at $11.44 on Friday. HUTCHMED has a 12-month low of $9.77 and a 12-month high of $19.50. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.83 and a current ratio of 4.96. The business has a 50 day simple moving average of $11.69 and a 200 day simple moving average of $13.56.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.